MarketsandMarkets

Next - Gen Immuno Oncology Conference - EU Edition

5th - 6th October 2023

The Westin Grand Frankfurt, Germany

Transforming cancer care through innovative immunotherapies

Over the past 6 years, Marketsandmarkets Next-Gen Immuno-Oncology conference has become the leading annual meeting focusing on the next wave of biotherapeutics, advances in technologies, and the valuable exchange of high-quality research from all disciplines of immuno-oncology. Marketsandmarkets IO congress provides access to a comprehensive 2-day program for participants to evaluate bi- or multi-specific biotherapeutics, explore the latest developments in existing and emerging cellular therapies, develop predictive preclinical models for translational strategies, appraise AI and computational tools for the discovery of new targets, target classes, and combinations to overcome resistance.

Our inaugral MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 5th – 6th October 2023, at The Westin Grand Frankfurt, Germany, would address the challenges and future directions in IO research.

This conference will highlight the current state of immuno-oncology for cancer care professionals with emphasis on current research, utilization trends, and advances in immunotherapies. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. With more than 20 speakers across the world from pharma, biopharma and biotech companies, the congress will discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy

WHAT TO EXPECT

  • Updates in development of ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
  • Biomarkers and Personalized Medicine in IO
  • CAR-T Cell therapy, TCR Based-Cell Therapy
  • Tumour microenvironment and Oncolytic Viruses

  • Exclusive conference to learn about antibodies, cellular therapy, and immune-checkpoint research under one roof.
  • Find out new case studies of immune-oncology projects in development.
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you.
  • Explore the latest platforms and technologies on the market for development.
  • Discuss the best tool for your research in immune oncology.
  • Share your work and achievements with your industry peers in the Poster Session

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

  • Monoclonal and Bispecific Antibodies
  • Cell Therapy
  • Immune Checkpoint Inhibitors

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

Allan Stensballe

Allan Stensballe, Associate Professor, Aalborg University

08:55 - 09:00

Novel Targets and Therapeutic Approaches in Immuno-Oncology

Keynote Presentation – Biomarker considerations in Immuno-Oncology drug development

Vaios Karanikas

Vaios Karanikas, Biomarker Experimental Medicine Leader, Oncology, Roche

09:00 - 09:35

Synthetic VHHs as building blocks for bi-specific T cell engagers

Bill Eldridge

Bill Eldridge, CEO, CSO, Isogenica

09:35 - 10:10

Drug Target Humanized Mouse Models for Evaluating Novel Therapeutics In Vivo

James Jin

James Jin, Vice President , Biocytogen

10:10 - 10:45

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:45 - 11:30

Targeting noncanonical epitope presented by HLA class I molecules in immuno-oncology

Michele Mishto

Michele Mishto, Reader, King’s College London

11:30 - 12:05

Navigating Multimodal Biomarker Data with the Veracyte Biopharma Atlas

Valerie Balme

Valerie Balme, Associate Director, Business Development, Biopharma

12:05 - 12:40

Accelerating Discovery and Unveiling Cellular Insights: Accelerate Your Research with Revvity’s Advanced Immunoassay Solutions

Fabienne Charrier Savournin

Fabienne Charrier Savournin, Life Sciences Technology Platform High Content Reagents Leader, Revvity Inc

12:40 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meeting

13:15 - 14:15

Anti-CD270 antibody checkpoint inhibitor for cancer treatment: Swing around patient’s CD270 immunosuppressive disadvantage

Louis Boon

Louis Boon, CSO , JJP Biologics

14:15 - 14:50

Understanding the effects of small molecule cancer therapies on the anti-tumour immune response

Philip Beer

Philip Beer, Chief Scientific Officer, Step Pharma

14:50 - 15:20

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Illip Burmester

Illip Burmester, Technical and Applications Manager, Proteome Sciences

15:20 - 15:55

Evening Refreshments and Poster Presentation | One-to-One Networking Meetings

15:55 - 16:40

Antibody-drug conjugates (ADCs) against triple-negative breast cancer (TNBC) using pathway-specific inhibitors

Anthony Cheung

Anthony Cheung, Research Associate, King’s College London

16:40 - 17:15

Closing Remarks from the Chairperson

17:15 - 17:15

Drinks Reception & Networking

17:15 - 17:15

End of Day 1

17:15 - 17:15

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

Pier Francesco Ferrucci

Pier Francesco Ferrucci, NIBIT President, Oncology Department Director, Multimedica Group

08:55 - 09:00

Combination Therapies, Tumour Micro-Environment and Personalized Medicine

Unlocking Immuno-Oncology Success: Elevating Industry Impact with Quality of Life endpoints in Cancer Clinical Trials

Andrew Bottomley

Andrew Bottomley, Independent Outcomes Research Consultant, Bottomley Consulting Group

09:00 - 09:35

Precision Proteomic Landscape of health-to-disease transitions of Rheumatic Musculoskeletal disorders and links to Cancer associate irAEs

Allan Stensballe

Allan Stensballe, Associate Professor, Aalborg University

09:35 - 10:10

Neoadjuvant approaches and research in locally advanced melanoma

Pier Francesco Ferrucci

Pier Francesco Ferrucci, NIBIT President, Oncology Department Director, Multimedica Group

10:10 - 10:45

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:45 - 11:30

Small Molecule Cancer Immunotherapy via Allosteric Modulation of the Adenosine Pathway

David Pejoski

David Pejoski, CEO, Adoram Therapeutics

11:30 - 12:05

Single-Cell Sequencing in Rare Diseases and our Research is now more focusing on Therapeutics of Rare Diseases: Using Autologous Stem Cell Therapy in the Area of Muscle Diseases and Cancer.

Rick Kamps

Rick Kamps, Head Research Engineer in the Department of Toxicogenomics, Maastricht University

12:05 - 12:40

Intravenous delivery of oncolytic virotherapy - a trojan horse approach

Faith Howard

Faith Howard, Co-Founder, NANOncolytics

12:40 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Autoimmune response against oxidative neoepitopes

Ahuva Nissim

Ahuva Nissim, Professor, Antibody and Therapeutic Engineering, Queen Mary University of London

14:15 - 14:45

Novel therapies targeting solid tumours

Ariel Marcotegui

Ariel Marcotegui, Medical Science Liaison – Oncology, Amgen

14:45 - 15:20

Closing Remarks from the Chairperson

15:20 - 15:20

End of Conference

15:20 - 15:20

SPEAKERS

Anthony Cheung

Anthony Cheung

Research Associate, King’s College London

Allan Stensballe

Allan Stensballe

Associate Professor, Aalborg University

Faith Howard

Faith Howard

Co-Founder, NANOncolytics

Louis Boon

Louis Boon

CSO , JJP Biologics

James Jin

James Jin

Vice President , Biocytogen

Michele Mishto

Michele Mishto

Reader, King’s College London

David Pejoski

David Pejoski

CEO, Adoram Therapeutics

Bill Eldridge

Bill Eldridge

CEO, CSO, Isogenica

Pier Francesco Ferrucci

Pier Francesco Ferrucci

NIBIT President, Oncology Department Director, Multimedica Group

Illip Burmester

Illip Burmester

Technical and Applications Manager, Proteome Sciences

Fabienne Charrier Savournin

Fabienne Charrier Savournin

Life Sciences Technology Platform High Content Reagents Leader, Revvity Inc

Philip Beer

Philip Beer

Chief Scientific Officer, Step Pharma

Ariel Marcotegui

Ariel Marcotegui

Medical Science Liaison – Oncology, Amgen

Vaios Karanikas

Vaios Karanikas

Biomarker Experimental Medicine Leader, Oncology, Roche

Rick Kamps

Rick Kamps

Head Research Engineer in the Department of Toxicogenomics, Maastricht University

Andrew Bottomley

Andrew Bottomley

Independent Outcomes Research Consultant, Bottomley Consulting Group

Valerie Balme

Valerie Balme

Associate Director, Business Development, Biopharma

Ahuva Nissim

Ahuva Nissim

Professor, Antibody and Therapeutic Engineering, Queen Mary University of London

FAQ

We offer various sponsorship packages that cater to different levels of exposure and engagement. These opportunities range from platinum, gold, and silver sponsorships to customized packages based on your marketing objectives and budget.
As a sponsor, you can expect benefits such as prominent branding in conference materials, website, and marketing collateral. Additionally, you will have the opportunity to address the audience during the event and network with key decision-makers and industry leaders.
We provide numerous avenues to maximize your brand visibility, including logo placements, sponsored sessions, exhibition booths, and sponsored networking events. Engaging attendees through product demos and interactive displays is also encouraged.
Yes, we understand the importance of aligning sponsorships with specific marketing goals. Our team can work with you to create a customized package that best suits your objectives and budget constraints.
Absolutely! We encourage sponsors to customize their packages with activities that resonate with their target audiences, such as branded merchandise, sponsored workshops, or exclusive sessions.
To ensure adequate planning and promotion, we recommend securing your sponsorship spot as early as possible. However, we will accommodate sponsorships until all available slots are filled.
The MarketsandMarkets Next-Gen Immuno Oncology Conference - EU Edition attracts a diverse audience, including industry experts, researchers, healthcare professionals, and key stakeholders. The expected size of the audience will be based on historical data and promotional efforts.
Yes, as a sponsor, you will have access to exclusive networking sessions and opportunities to interact with key decision-makers, industry leaders, and fellow sponsors.
Sponsors receive prominent recognition in conference materials, promotional materials, and on the event website, based on their sponsorship level.
Certainly! Some successful sponsor activations from previous conferences include interactive booths with engaging displays, sponsored networking sessions, and branded promotional giveaways that left a lasting impression on attendees.

ENQUIRE NOW

SPONSORS

PARTNERS

LOCATION

Venue

The Westin Grand Frankfurt, Germany

PAST EVENT GALLERY